Abstract
Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-69 |
| Number of pages | 5 |
| Journal | Parkinsonism and Related Disorders |
| Volume | 56 |
| DOIs | |
| State | Published - Nov 1 2018 |
Fingerprint
Keywords
- Botulinum toxin
- Clinical trial
- Essential tremor
- IncobotulinumtoxinA
ASJC Scopus subject areas
- Neurology
- Geriatrics and Gerontology
- Clinical Neurology
Cite this
Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. / Mittal, Shivam Om; Machado, Duarte; Richardson, Diana; Dubey, Divyanshu; Jabbari, Bahman.
In: Parkinsonism and Related Disorders, Vol. 56, 01.11.2018, p. 65-69.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach
AU - Mittal, Shivam Om
AU - Machado, Duarte
AU - Richardson, Diana
AU - Dubey, Divyanshu
AU - Jabbari, Bahman
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.
AB - Introduction: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of essential hand tremor. In essential tremor and Parkinson's disease tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor but a high percentage of patients (30–70%) develop moderate to severe hand weakness which has limited its use in clinical practice. Methods: This study was performed from July 2013 to July 2016 on 33 subjects. This is a double-blind, placebo-controlled, crossover trial injecting 80–120 units of IncoA into 8–14 hand and forearm muscles using a customized approach. The subjects were followed for 28 weeks. The treatment efficacy was evaluated by the Fahn Tolosa Marin tremor rating score and NIH genetic criteria for tremor severity at 4 and 8 weeks after each of the two sets of treatments. Hand strength was assessed by an ergometer. Results: There was statistically significant improvement in clinical rating score of tremor at 4 and 8 weeks following the IncoA injection. Conclusion: In this study, injection of IncoA treatment via a customized approach improved essential tremor on the clinical scales and patient's perception with a low occurrence of significant hand weakness.
KW - Botulinum toxin
KW - Clinical trial
KW - Essential tremor
KW - IncobotulinumtoxinA
UR - http://www.scopus.com/inward/record.url?scp=85048811753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048811753&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2018.06.019
DO - 10.1016/j.parkreldis.2018.06.019
M3 - Article
C2 - 29929813
AN - SCOPUS:85048811753
VL - 56
SP - 65
EP - 69
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
ER -